

CUMULATIVE INDEX 1999

Volume 17

February	CARDIOVASCULAR DISEASE IN THE ELDERLY, pages 1-245
May	UNSTABLE ANGINA, pages 247-441
August	STRESS ECHOCARDIOGRAPHY, pages 443-608
November	DISEASES OF THE AORTA, pages 609-854

Note: Page numbers of article titles are in **boldface** type.

Abciximab, 349, 350
Aging. See also *Elderly*.
and cardiovascular disease, **51-65**
abdominal aneurysm in, 58, 59
ankle-brachial blood pressure and, 56-58
brain pathology in, subclinical, 59, 60
carotid artery disease in, 57-59
coronary and aortic calcification in, 60-62
echocardiographic changes in, 60
endothelial function in, 62-64
prevalence of subclinical disease in, 54-56
subclinical measurements in, **51-65**
vascular stiffness in, 62
cardiovascular consequences of, **35-49**
and exercise response in humans, 42-47
challenges of studying, 35, 36
in animal models, 36, 37
in humans, 36-39
response to catecholamines and, 39
cardiovascular pharmacology of, **17-34**
in the United States, 1-3
Amiodarone, pharmacology of, in the elderly, 29, 30
Amyloidosis, in the elderly, 167-169
familial, 169
primary, 168, 169
Ancrod, 338
Aneurysm(s), abdominal, in the elderly, 58, 59
aortic, 615-625, 630, 631, 697, 698
adventitial lamellar degeneration and, 622
arteriosclerosis and, 617, 618
ascending, 623
changes in aortic wall and, 619-622
chronic dissection and, 617
chronic obstructive pulmonary disease and, 616, 617
clinical features of, 703, 704
descending, 624
diagnostic approaches to, 703, 704
epidemiology of, 700
etiology of, 623-625
family history in, 624, 625
hypertension and, 616, 617
imaging of, 674-676, 705
in Marfan syndrome, 623, 624, 708
in multiple sites, 618
natural history, pathogenesis, and etiology of, **615-635**
natural history of, 615-619, 706-708
normal aging effects and, 622
pathogenesis of, 619-622, 701
risk factors for, 701
size of, 616, 618, 619
smoking and, 617
surgical treatment of, 709, 710
survival rates in, 618
syphilis and, 617
thoracic, 226, 227
timing of surgical intervention for, 706-708
versus Marfan syndrome, 688, 689
atherosclerotic, imaging findings in, 674-676
definition of, 739
mycotic, imaging findings in, 676
thoracic aortic, alternative estimation strategy in evaluation of data on, 799, 800
complication rates of, 829, 830
conventional versus instrumental variables estimation approach to interpretation of data on, 800, 801
developing surgical intervention criteria for, **827-839**
growth rates of, 828-839
interpreting data on, **797-805**
long-term survival following, 833, 834
measurement error in evaluation of, 798
prophylactic repair of in Marfan syndrome, 837
risk factor analysis and, 799, 800
selection bias in interpretation of data on, 801-803
thoracoabdominal aortic, operative technique for, 754-761
preoperative evaluation of, 753, 754
preventing ischemic complications after surgical treatment of, 762, 763
results of surgical treatment of, 762
surgical treatment of, 753-761
with acute distal aortic dissection, surgical treatment of, 761, 762
with concomitant proximal aortic disease, staged surgical repair of, 761
treatment of, early history of, 609
in early modern period, 609, 610

Aneurysm(s) (Continued)
 in the modern era, 610, 611

Angina, unstable. See *Unstable angina*.

Angiography, coronary, early use of in unstable angina, 373-386
 for unstable angina, 425

Angioplasty, coronary, percutaneous transluminal, 391-396, 425-429
 in unstable angina, 253, 254

Angiotensin-converting enzyme, for heart failure, in the elderly, 126, 127

Angiotensin-converting enzyme inhibitors, pharmacology of, in the elderly, 30

Anticoagulants. See also specific types, e.g., *Thrombin inhibitors*.
 for unstable angina, 327-343
 comparison of, 339, 340
 duration of therapy with, 340
 naturally occurring, 339
 novel, 338, 339
 overview of, 327, 328

Antihypertensive drugs, in the elderly, economic considerations in selection of, 88
 indications and contraindications of, 85-87
 morbidity and mortality trial experience in, 85, 86
 predicted efficacy of, 87, 88
 quality-of-life issues in selection of, 88, 89
 selection of, 85-89

Antiplatelet therapy, for treatment of acute coronary syndromes, 345-357
 for unstable angina, 416
 recommendations for, 353, 354
 role of in maintenance of patency following acute coronary syndrome, 346, 347

Antistasin, 339

Antithrombin III, 339

Antyllus, 609

Aorta, ascending, atherosclerotic disease in, severe, 748, 749
 complex problems of, 748, 749
 endocarditis and, 748
 replacement of, 741, 742
 surgical techniques for, 739-750
 terms and definitions of, 739-741
 use of biological glue in replacement of, 785-788

atherosclerotic disease of, 711, 712

elastic properties of, indexes of, 722-726
 methodological considerations in measurement of, 726

wave reflections and aortoventricular coupling as measures of, 726, 727

function of, measurement of, 721-724

medical treatment of, part I, 697-715
 part II, 717-737

pathology of, 718-721

spontaneous echocardiographic contrast in, 720, 721

structural failure of, mechanisms of, 720

thoracic. See *Thoracic aorta*.

thoracoabdominal, indications for surgery of, 752, 753
 surgical techniques for, 751-765

Aortic arch, replacement of, use of biological glue in, 788, 789
 surgical repair of, results of, 775, 776
 techniques in, 770-775

surgical techniques for, 767-778

Aortic disease, definition, incidence, and classification of, 697-701
 genetic basis of, 683-695

Aortic distensibility, 722
 effect of age on, 726, 727

effect of heart rate on, 728
effect of smoking on, 727, 728

Aortic dysfunction, reversibility of, by intra-aortic balloon counterpulsation, 731
 future directions in, 734, 735

in hyperlipidemia, 729, 730

in hypertension, 728, 729
 in postmenopausal women, 730, 731

surgical remedies for, 733

Aortic energy loss, 726

Aortic pressure-diameter relation, 722, 724, 725

Aortic regurgitation, in the elderly, 151, 152
 stress echocardiography in, 566-568

Aortic root replacement, 742-748
 grafts in, composite, 742, 743
 homograft, 743-745
 porcine xenograft, 745
 pulmonary valve autotransplant, 745-747
 Ross procedure for, 745-747
 valve-sparing, 741, 747, 748

Aortic rupture, 740

Aortic stenosis, stress echocardiography in, 563-566

Aortic stiffness constant, 723, 725

Aortic strain, 722

Aortic surgery, use of biological glue in, 779-796
 future of, 792, 793
 results of, 790, 791

Aortic valve disease, in the elderly, 137-146
 asymptomatic, 142
 diagnosis of, 141, 142
 etiology and pathology of, 138, 139
 physical examination for, 140, 141
 prevalence of, 137, 138
 prosthetic valves in, 146
 symptomatic, 143, 144
 symptoms of, 139, 140
 treatment of, 144-146

Aortic valve repair, use of biological glue in, 787-788

Aortic valve replacement, stress echocardiography in
 assessment of, 568, 569

Aortic wall, hemodynamic forces on, 702
 intrinsic properties of, 701, 702

Arachnodactyly, contractual, congenital, versus Marfan syndrome, 689

Argatroban, 337

Aspirin, as antiplatelet agent, 347, 348
 for heart failure in the elderly, 128, 129
 for unstable angina, 360, 416, 417
 prevention of, 252

Atherectomy, coronary, for unstable angina, 430, 431

Atherogenesis, and plaque progression, 263, 264

Atherosclerosis, 51-54
 aortic, 711-713
 plaque rupture and, in unstable angina, 263-270

Atherosclerotic lesions. See also *Plaque, atherosclerotic*.
 classification of, 283-285
 origin of, 283
 phases of, 283-285

Atrial pacing, transesophageal, 531, 532

Autotransplant, of pulmonary valve, for aortic root replacement, 745-747

Baby boomers, aging of, 1-3

Bahnsen, Henry, 611

Beals syndrome, 688

Beta blockers, aortic function and, 731, 732
 for heart failure in the elderly, 128
 for unstable angina, 362, 363, 418

Beta-adrenergic antagonists, pharmacology of, in the elderly, 30

Calcium channel antagonists, 128
for unstable angina, 363, 364, 418, 419
pharmacology of, in the elderly, 30, 31

Cardiac function, effect of aging process on, and
vascular changes in animal models and humans, 39-42

disease factors in, 38, 39, 42, 46
in animal models, 36
in humans, 36-39

lifestyle factors in, 38, 41, 42, 46, 47
response to catecholamines in animal models and, 39

response to catecholamines in humans and, 42-47

Cardiomyopathies, in the elderly, 159-172
hypertensive hypertrophic, 163-166
hypertrophic, 159-166
hypertrophic obstructive, 160-163
restrictive, 166-170

Cardiovascular disease, aging and. See *Aging, and cardiovascular disease*.
in the elderly, and heterogeneity of aging process, 5, 6
challenge of health care delivery in, 1-15
coronary revascularization procedures and, 7-9
cost implications of, 6, 7
cost-effectiveness issues and, 10, 11
defining old age and, 5
defining therapeutic goals in, 6
epidemiology of, 2, 4, 5
future approaches to cost containment and, 11-13
lack of research data on, 5
management of, 5, 6
Medicare and, 9, 10

Cardiovascular surgery, in the elderly, 213-231
complications of, 217, 218
preoperative evaluation and, 213-216
procedures in, 216-228

Cardioverter defibrillator, implantable, in the elderly, cost-effectiveness of therapy with, 193, 194

Carotid artery disease, in the elderly, 57-59

Carrel, Alexis, 610

Cerebral perfusion, in deep hypothermic circulatory arrest, antegrade, 769, 770
retrograde, 769

Chest pain, evaluation of, 307-326
clinical symptoms and signs of, 308, 309
echocardiography in, 320-322
electrocardiac, 309-311
exercise treadmill testing in, 318, 319
radionuclide perfusion imaging in, 319, 320
triage of, using predictive models, 311-313

Chest pain observation units, in evaluation of chest pain patients, 322

Circulatory arrest, deep hypothermic. See *Deep hypothermic circulatory arrest*.

Clopidogrel, 348, 349
for unstable angina, 417, 418

Coagulation abnormalities, in the acute coronary syndromes, 283-294

Computed tomography, for imaging of thoracic aortic disease, 659-663
indications for, 662, 663
overview of, 659, 660
spiral, 660
technique of, 660
three-dimensional, 660-662

volume rendering in, 660-662

Consumer Bill of Rights for Health Care, 70, 71

Cooper, Astley, 610

Coronary artery bypass graft, in the elderly, 219-221
combined procedures in, 223
repeated procedure in, 221, 222
in unstable angina, 253, 254

Coronary artery disease, in the elderly, inoperable, 224

Coronary artery dissection, peripartum, associated with non-Q wave myocardial infarction, 404-406

Coronary heart disease, in the elderly, cardiac
rehabilitation and, 116
clinical aspects of, 94-96
stable and unstable syndromes of, 93-122. See also *Coronary syndromes, acute and Ischemic syndromes, stable*.

Coronary syndromes, acute, in the elderly, 104-113

DeBakey, Michael, 611

Deep hypothermic circulatory arrest, in surgery of the aortic arch, 767-769
clinical data in, 768, 769
experimental data in, 768

Depression, in unstable angina, 251, 252

Digoxin, for heart failure, in the elderly, 127, 128
pharmacology of, in the elderly, 31

Dipyridamole, historical background of, 481, 482
in transesophageal stress echocardiography, for evaluation of coronary artery disease, 505

Dipyridamole stress echocardiography, 481-499, 529,
530
diagnostic accuracy of, 485, 486
electrocardiogram during, 486
future of, 494, 495
hyperemic stress and, 482
in assessment of myocardial viability, 491, 492
in women, 575
prognostic effectiveness of, 576
increased oxygen demand in, 484, 485
ischemic stress and, 482
justification for use of, 494
pathophysiologic basis of, 482-484
perfusion scintigraphy versus two-dimensional echocardiography in, 489
prognostic value of, 489-491
tolerability and safety of, 492-494
versus dobutamine stress echocardiography, 487-489
versus exercise echocardiography, 489

Dissection, aortic, 625-630, 631, 632, 698-700
atherosclerosis and, 641
choosing an imaging modality for, 668, 669
classic, 637-641
clinical features of, 704
definition of, 739
diagnostic approaches to, 704
epidemiology of, 700, 701
etiology of, 630
imaging of, 668-672, 705, 706
imaging pitfalls in, 671
in Marfan syndrome, 629, 630
intimal tear in, 703
intraoperative use of biological glue in, 784, 785
long-term management of, 711
medical therapy for, 709
natural history, pathogenesis, and etiology of, 615-635
natural history of, 626-629
pathogenesis of, 629, 630, 701

Dissection (Continued)

- pathologic variants of, 637-657
- risk factors for, 701
- surgical treatment of, 710, 711
- type A, 626-629
- type B, 628, 629
- versus penetrating atherosclerotic ulcer and intramural hematoma, 645-653

Diuretics, for heart failure, in the elderly, 128

pharmacology of, in the elderly, 31, 32

Dobutamine, in transesophageal stress echocardiography, for evaluation of coronary artery disease, 505, 506

pharmacology of, 462

Dobutamine stress echocardiography, 461-479

- and atropine infusion in, 467
- clinical uses of, 469-472
- contraindications to, 469
- detection of myocardial hibernation with, 542, 543
- diagnostic accuracy of, 470, 471
- electrocardiographic, echocardiographic, and vital sign monitoring in, 467, 468
- historical development of, 461, 462
- hypotension and left ventricular outflow tract obstruction in, 464
- in assessment of myocardial viability, 471
- in diagnostic evaluation of chest pain, 469-471
- in diagnostic evaluation of known coronary artery disease, 471, 472
- in post-myocardial infarction assessment, 471
- in valvular heart disease, 474
- in women, 575
- prognostic effectiveness of, 576

infusion endpoints in, 466

laboratory setup and personnel for, 466

Ohio State University protocol of, 466-468

pathophysiology of, 462-464

prediction of reversible dysfunction with, following acute myocardial infarction, 540

protocols of, 464-468

risk stratification in, 472-474

- for chest pain patients, 472
- for known coronary artery disease, 472
- preoperative, for noncardiac surgery, 472-474
- safety and complications of, 468, 469
- versus myocardial perfusion techniques, 543-547
- versus nuclear perfusion imaging, 474, 475
- versus perfusion imaging, 540

Echocardiography, advantages and disadvantages of, 599

stress. See *Stress echocardiography*.

Ectopia lentis, familial, versus Marfan syndrome, 690

Ehlers-Danlos syndrome, aortic dissection in, 629, 630, 638-640

Elderly. See also *Aging*.

cardiovascular disease in. See *Cardiovascular disease, in the elderly*.

challenge of health care delivery to, 1-15

hypertension in. See *Hypertension, in the elderly*.

Electrocardiogram, advantages and disadvantages of, 599

Endocarditis, in ascending aorta, 748

- infective, in the elderly, 152, 153

Endovascular solutions for thoracic aortic disease, 815-825

- in aneurysms of the descending thoracic aorta, 815-818
- in aortic dissection, 820-822
- acute, 822-824
- in malperfusion syndromes, 820-822
- second generation endografts and, 818-820

Eptifibatide, 350, 351

Exercise, echocardiography, imaging modalities in, 450

- in prevention of unstable angina, 252

Exercise echocardiography, 447-460, 525-528

- accuracy of, 452-455
- advantages and disadvantages of, 451, 452
- analysis methods in, 450, 451
- electrocardiogram in, 601, 602
- in women, 574, 575
- prognostic effectiveness of, 576
- isometric stress in, 450
- methodology of, 448
- performance methodology of, 448-456
- postinfarct prognosis and, 456
- post-treadmill imaging in, 448, 449
- problems and future developments of, 456
- prognostic implications of, 454, 456
- role of techniques of, 452
- supine bicycle ergometry in, 449
- upright bicycle ergometry in, 449, 450
- versus radionuclide techniques, 454

Exercise electrocardiogram, as stress test modality, 601, 602

Exercise testing, advantages and disadvantages of, 600

Exercise treadmill testing, in chest pain evaluation, 318, 319

Factor Xa inhibitors, 338, 339

Fibrillation, atrial, in the elderly, 173-188

- approach to the patient in, 177-179
- atrial pathophysiology associated with, 173-175
- cause of, 175
- chronic, management of, 179-182
- congestive heart failure and, 175, 176
- emboli and, 176, 177
- implantable atrial defibrillators, 184, 188
- intermittent, management of, 182, 183
- long-term anticoagulation therapy for, 180-182
- pacemakers for, 184
- prevalence of, 173
- prognosis in, 175-177
- radiofrequency ablation in, 184
- reversion of, 183, 184
- surgical maze in, 184

Fibrillinopathies, 683

Fibrin glue, 783, 784

- clinical use of, 784, 785
- in cardiac and aortic surgery, 783, 784

Galen, 609

Gelatin-resorcinol-formalin (GRF) glue, 780-782

- clinical use of, 784, 785
- in surgery for acute aortic dissection, 782, 783

Glue, biological, fibrin, 783, 784

- gelatin-resorcinol-formalin, 780-782
- use of in aortic surgery, 779-796

GP IIb-IIIa antagonists, 349-353

- oral, 352, 353

Graft(s). See also *Coronary artery bypass grafts*.

- composite, in aortic root replacement, 742-744
- Gross, Robert, 611
- Guthrie, Charles, 610

Heart failure, in the elderly, 123-135
 activity prescription in, 131, 132
 clinical features of, 124-126
 diagnostic evaluation of, 125, 126
 diastolic, 129, 130
 epidemiology of, 123
 ethical and end-of-life decisions in, 132
 etiology and precipitating factors of, 124, 125
 management of, 126-132
 nonpharmacologic treatment of, 130, 131
 pathophysiology of, 123, 124
 prevention of, 132
 symptoms and signs of, 125
 systolic, 126-129
 systolic versus diastolic, 126
 with normal systolic function, 124

Hematoma(s), intramural, 644
 definition of, 740
 imaging findings in, 672-674
 versus classic aortic dissection and penetrating atherosclerotic ulcer, 645-653

Heparin, for unstable angina, 360, 361, 420
 low-molecular-weight, 331-334
 advantages of over unfractionated heparin, 331, 332
 clinical trials supporting, 332-334
 for unstable angina, 420-423
 history of, 331
 limitations of, 334
 structure and mechanism of action of, 331

Unfractionated, 328-331
 clinical trials supporting, 329, 330
 complications of therapy with, 330
 history of, 328
 limitations of, 330, 331
 structure and mechanism of action of, 328, 329
 versus low-molecular-weight heparin, 331, 332
 versus hirudin, 335

Heparinoids, 334

Hirudin, 335, 336
 low-molecular-weight, 423, 424
 versus heparin, 335

Hirulog, 336, 337

Homocystinuria, versus Marfan syndrome, 689

Homografts, in aortic root replacement, 743-745

Hunter, John, 609

Hyperlipidemia, aortic dysfunction in, reversibility of, 729, 730

Hypertension, aortic dysfunction in, reversibility of, 728, 729
 in the elderly, 79-91
 blood pressure goals of therapy for, 84, 85
 blood pressure levels for initiation of drug therapy for, 83, 84
 classification and prevalence of, 80
 epidemiology of, 79, 80
 left ventricular hypertrophy and, 236-238
 lifestyle changes in treatment of, 80, 81
 morbidity and mortality trials in, 81-83
 pulse pressure and risk in, 79, 80
 risk of systolic and diastolic blood pressure, 79
 selecting drugs for. See *Antihypertensive drugs, in the elderly*.

Ischemic syndromes, stable, in the elderly, catheter-based interventions for, 101-104
 coronary arteriography in, 99, 100
 coronary artery bypass grafting for, 101-104
 drug therapy for, 100, 101

management of, 100-104
 noninvasive testing in, 97-99
 physical examination for, 97

Lamifiban, 351, 352

Lipid-lowering therapy, in prevention of unstable angina, 252

Magnetic resonance imaging, in thoracic aortic disease, contrast-enhanced, 665, 666
 indications for, 666
 overview of, 663
 time-of-flight, 663, 665
 traditional, 663

Managed care, for older patients with cardiac disease, 71-75
 cardiovascular disease management in, 72, 73
 creative approaches to, 73, 74
 promises and perils of, 67-77
 for the elderly, 69-71
 history of, in younger and older populations, 67-69

Marfan, Antoine, 683

Marfan syndrome, 683-695
 aortic aneurysm in, 623, 624
 aortic dissection in, 629, 630, 638-640, 687
 aortic root enlargement in, 687
 cardiovascular manifestations of, 685, 687
 diagnosis of, 684-688
 differential diagnosis of, 689-690
 elastin-associated microfibrils in, 684
 FBN1 gene in, 684
 FBN1 gene mutation analysis in, 690
 fibrillin biochemical studies in, 691
 fibrillin immunofluorescence studies in, 691
 genetic linkage analysis in, 690
 laboratory diagnosis of, 690
 management of, 691-694
 cardiovascular problems and, 692-694
 in pregnant patients, 694, 695
 ocular problems and, 694
 skeletal problems and, 694
 MASS phenotype and, 689, 690
 medical therapy in, 708, 709
 mitral valve prolapse in, 688
 molecular basis of, 683, 684
 natural history of, 691
 neonatal, 688, 689
 ocular manifestations of, 685
 skeletal manifestations of, 685
 thoracic aneurysms in, 708

Marfan-like connective tissue disorder, 690

Matas, Rudolph, 610

Medicare Health Maintenance Organizations (HMOs), 68, 69

Medicare Risk Program, 68

Medicine Versus Angiography in Thrombolytic Exclusion Trial, 381

Mitral valve annular calcification, in the elderly, 146, 147

Mitral valve prolapse (MVP) syndrome, familial, versus Marfan syndrome, 690

Mitral valve regurgitation, in the elderly, 147-150
 stress echocardiography in, 561-563

Mitral valve replacement, evaluation of, stress echocardiography in, 563

Mitral valve stenosis, in the elderly, 150, 151
stress echocardiography in, 556-561

Mortality compression, 1

Myocardial hibernation, 541, 542

Myocardial infarction, acute, in the elderly, 105-113
clinical presentation of, 106
electrocardiographic findings and enzyme studies in, 106, 107
management of, 108-113
prognosis of, 107, 108
risk stratification and management after, 113-116

Myocardial injury, biochemical markers of, 313-318
in diagnosis and prognostication of acute coronary syndromes, 316, 317
in diagnosis of acute myocardial infarction, 314-316
point-of-care testing for, 317, 318

Myocardial ischemia detectors, 599, 600

Myocardial stunning, 539, 540

Myocardial viability, after acute myocardial infarction, clinical relevance of, 540, 541
assessment of with stress echocardiography, 539-553
clinical implications of, in left ventricular dysfunction, 550, 551
contractile function versus perfusion in assessment of, 547, 548
in chronic coronary artery disease and left ventricular dysfunction, clinical importance of, 548-550
myocardial contrast echocardiography for assessment of, 545-547
radionuclide techniques for assessment of, 543-545

Nitrates, aortic function and, 732, 733
for unstable angina, 361, 362, 419, 420
pharmacology of, in the elderly, 32

Noncardiac surgery in the elderly, assessment of
cardiovascular risks in, 197-211
age-related changes and implications for surgery in, 200-202
intraoperative management of, 206-208
patient factors in, 197, 198
postoperative management of, 208
preoperative assessment and management of, 202-206
procedure factors in, 198
protocol factors in, 199
provider factors in, 198, 199
surgical outcomes and aging in, 199, 200

Noonan syndrome, aortic dissection in, 638-640

Nuclear perfusion imaging, advantages and disadvantages of, 599

Ochsner, Alton, 611
Osler, William, 610

Pain, aortic, 718-720

Paré, Ambrose, 609

Penetrating atherosclerotic ulcers, 641-644
versus classic aortic dissection, 645-656

Pharmacokinetics, age-related changes and, 17-22

Pharmacology, cardiovascular, of aging, 17-34
absorption and, 18
β-adrenergic antagonists and, 30
adverse drug reactions and, 24-29
amiodarone and, 29, 30

angiotensin-converting enzyme inhibitors and, 30
bioavailability and, 18, 19
biotransformation and elimination and, 20
calcium channel antagonists and, 30, 31
digoxin and, 31
discontinuation of cardiovascular medication and, 28, 29

distribution and, 19, 20
diuretics and, 31, 32
drug clearance and, 20
drug-disease interactions and, 27-29
drug-drug interactions and, 25-27
drug-nutrient interactions and, 26-28
elimination half-life and, 22
hepatic clearance and, 20, 21, 23
nitrates and, 32
nonhepatic, nonrenal drug clearance and
biotransformation and, 22, 23
pharmacodynamics and, 22, 24
renal clearance and, 21, 23

Plaque, atherosclerotic. See also *Atherosclerotic lesions*.
assessment of, by angiography, 296-298
by angiography, 298-300
by intracoronary ultrasound, 300-303
classification of, 283-285
clinical sequelae of rupture of, 289, 290
disruption of, 268
and thrombosis, 271-281
infection as trigger of, 275, 276
mechanical, hemodynamic, and emotional triggers of, 276
potential triggers of, 275-278
role of inflammation, metalloproteinases, and
apoptosis in, 272-275
thrombosis following, 275

fibrous cap of, thickness and composition of, 272
fissured or ruptured, composition of, 272-275
heterogeneity of, 264-266
histopathologic analysis of, 295, 296
inflammation and cap strength of, 268
lipid-rich core of, 266, 267
lipoprotein transport in formation of, 285, 286
progression of, atherogenesis and, 263, 264
role of infectious agents in instability of, 286
role of inflammatory cells in instability of, 286
rupture of, 286, 297
adjunctive therapies for, 292
antithrombotic and antiplatelet therapies for, 291
glycoprotein IIb/IIIa receptor antagonists for, 291, 292
histopathology of, 263-270
treatment of, 291, 292
stabilization of, 277, 278
thrombosis following rupture of, 288, 289
unstable, characterization of by angiography, angiography, and intravascular ultrasound, 295-305
vasospasm following rupture of, 289
vulnerability of, 266

Plaque rupture, prevention of, 733, 734

Preventive cardiology, diabetes and insulin resistance, 239
in the elderly, homocysteine and, 239
lipids and, 236
oxidation and, 239
smoking and, 238, 239

Prostheses, aortic, 740, 741

Protein C, 339

Pseudoaneurysms, 676
definition of, 741

Radionuclide myocardial perfusion imaging, 532, 533

Recombinant tick anticoagulant peptide, 338, 339

Rehabilitation, cardiac, in the elderly, 233-242

- Ochsner studies of, 234, 235
- Ross procedure, for aortic root replacement, 745-747

Scoliosis, in Marfan syndrome, management of, 693

Selection bias in interpretation of data, 801-803

- correcting for, 802, 803
- definition of, 801, 802

Sinus of Valsalva, aneurysm and fistula of, 748

Smoking cessation, in prevention of unstable angina, 251

Spinal cord, protection of during thoracic aortic surgery, 807-813

- adjuncts to aneurysm repair and, 810-812
- delayed postoperative paraplegia and, 812
- effects of clamping the descending thoracic aorta and, 808, 809
- ischemia and, 808
- minimizing cord ischemia during aortic clamping as, 809, 810
- relevant arterial anatomy in, 807, 808

Stenting, intracoronary, for unstable angina, 429, 430

Stickler syndrome, versus Marfan syndrome, 690

Stress echocardiography, 602

- arbutamine, 475, 476
- choice of stress test in, 600, 601
- choosing the appropriate modality in, 597-606
- cost effectiveness of, 583-595
 - analysis of, 583, 584
 - future directions in, 592, 593
 - issues in evaluation of, 584-592
- cost issues in, 585, 586
- dipyridamole. See *Dipyridamole stress echocardiography*
- dobutamine. See *Dobutamine stress echocardiography*
- effectiveness issues in, 586-592
 - in diagnosis of coronary artery disease, 587, 588
 - in patients after myocardial infarction, 589, 590
 - in patients after revascularization, 590, 591
 - in preoperative cardiovascular evaluation for non-cardiac surgery, 591, 592
 - in women, 588, 589
- evolution of, 443-446
- for risk assessment of patients after myocardial infarction, 521-538
 - application of, 525-532
 - applications of, 525-532
 - approaches to, 522-525
 - clinical aspects of, 523
 - exercise testing and, 524, 525
 - integrated approaches to, 534, 535
 - new developments in, 532
 - pathogenesis in, 522
 - rationale of, 522, 523
 - resting left ventricular function and, 523, 524
 - versus radionuclide myocardial perfusion imaging, 532, 533
- in aortic regurgitation, 566-568
- in aortic stenosis, 563-566
- in assessment of aortic valve replacement, 568, 569
- in mitral valve regurgitation, 561-563
- in mitral valve replacement, 563
- in mitral valve stenosis, 556-561
- in valvular heart disease, 555-572
- in women, 573-582
 - and test performance for chest pain diagnosis, 574, 575
 - cost effectiveness and diagnostic strategies of, 579, 580

factors affecting test performance of, 577, 578

- implications of a positive result for, 578, 579
- limitations of, 602, 603
- myocardial imaging in, 602
- myocardial ischemia detectors in, 599, 600
- pharmacologic, 461-479
- transesophageal. See *Transesophageal echocardiography with stress*.
- types of stressors in, 597-599

Stress myocardial imaging, 602

Stress myocardial perfusion imaging, 603, 604

Stress reduction, in prevention of unstable angina, 251, 252

Stroke, aortic imaging in, 679, 680

Stunning, myocardial, 539, 540

Surgery, cardiovascular, in the elderly. See *Cardiovascular surgery, in the elderly*.

 noncardiac, in the elderly. See *Noncardiac surgery in the elderly*.

Tachycardia, ventricular, in the elderly, ablative therapy for, 191

- electrophysiologic testing in, 190, 191
- implantable cardioverter defibrillator for, 192, 193
- pharmacologic therapy for, 191, 192
- prophylactic treatment of, 193
- treatment of, 189-193, 191-193
- triggers of, 189, 190

Thienopyridines, 348, 349

Thoracic aorta, surgery of, history of, 609-613

- modern era of, 610, 611
- ongoing challenges of, 611, 612

Thoracic aortic disease, imaging of, 659-682

- computed tomography in, 659-663
- magnetic resonance imaging in, 663-666
- transesophageal echocardiography in, 666-668
- summary of articles on and conclusions about, 841-845
- transthoracic echocardiography in imaging of, 668

Thrombin inhibitors, direct, 335-337

- indirect, 328-334

Thrombocytopenia, heparin-induced, 330

Thrombolysis, rheolytic, 411

Thrombolysis in Myocardial Infarction IIb Trial, 378, 379

Thrombolytic therapy, for unstable angina, 424

Thrombosis, acute, 288, 289

- following plaque rupture, 288
- prevention of, 290
- risk factors for, 289
- substrate dependency of, 288
- tissue factor dependency of, 289
- and plaque disruption, 271-281
- coronary, clinical manifestations of, 276, 277
 - in the acute coronary syndromes, 283-294

Thromboxane inhibitors, 347-349

Ticlopidine, 348, 349

- for unstable angina, 417

Tirofiban, 352

Transection, aortic, imaging of, 676, 677

Transesophageal echocardiography, in imaging of

- thoracic aortic disease, overview of, 666-668
- patient selection and contraindications in, 667
- preparation for, 667, 668
- procedural pitfalls of, 668
- technique of, 667, 668

Transesophageal echocardiography with stress

- dobutamine in, results of, 506-509
- for evaluation of coronary artery disease, 501-520

Transesophageal echocardiography with stress (Continued)
 atrial pacing in, 503-505
 dipyridamole in, 505
 dobutamine in, 505, 506
 evaluation of mechanism of chest pain and, 512-514
 in patients with left ventricular dysfunction, 514-518
 in women, 509-511
 ischemic threshold in, 511, 512
 stressors used in, 503-506
 technique of, 502, 503

Transthoracic echocardiography, in imaging of thoracic aortic disease, 668

Trauma, aortic, imaging findings in, 676-679

Treadmill testing, exercise, in chest pain evaluation, 318, 319

Troponins, cardiac, in diagnosis and prognostication of acute coronary syndromes, 316, 317

Tuffier, Theodore, 610

Turner syndrome, aortic dissection in, 638-640

Ulcer(s), atherosclerotic, penetrating. See *Penetrating atherosclerotic ulcers*.

United States, population of, changing demographics of, 1-3

Unstable angina, aggressive versus conservative therapy for, 387-399
 angioplasty procedures in, 253, 254
 anticoagulant treatment for, 327-343
 aspirin for, 360
 beta blockers for, 362, 363
 calcium antagonists for, 363, 364
 coronary arteriography in, 388
 coronary artery bypass graft in, 253, 254, 391, 392
 early use of coronary angiography and intervention in, 373-386
 timing of, 381-383
 United States practice patterns of, 374, 375
 worldwide practice patterns of, 373, 374
 health care burden of, 247-261
 heparin for, 360, 361
 high-risk subsets in, 401-404
 antianginal therapy for, 418-420
 antiplatelet therapy for, 416
 antithrombotic therapy for, 420-424
 aspirin therapy for, 416, 417
 case study of, 401, 402
 Clopidogrel for, 417, 418
 coronary angiography in, 425
 coronary atherectomy in, 430, 431
 interventional therapy for, 425-429
 intracoronary stenting in, 429, 430
 management of, 415-434
 medical therapy for, 416-418
 thrombolytic therapy for, 424
 Ticlopidine for, 417
 identification of high-risk patients with, without coronary angiography, 389, 390
 in patient with prior coronary artery bypass grafting, 409-412
 case study of, 409, 410
 in the elderly, 104, 105
 inpatient medical management of, 366-369

interesting cases of from the University of Texas Medical Branch, 401-414
 intervention strategies for, 253-256
 direct costs of, 253, 254
 new technology costs of, 255, 256
 nonmedical costs of, 254, 255
 intracoronary stent technology in, 255
 intracoronary thrombus and, 406-409
 case study of, 406
 invasive management of, practical issues of, 383
 invasive versus conservative management of, results from randomized trials of, 378-381
 measuring outcome in, 248-251
 by clinical events, 250, 251
 by economic analysis, 250
 by quality of life, 250
 nitrates for, 361, 362
 outpatient management of, 365, 366
 pathophysiology of, 359, 360
 peripartum, 404, 405
 prevention strategies for, 251-253
 prognosis of, with medical therapy, 387, 388
 rationale for consistent interventional treatment pathway in, 375-377
 risk stratification in, 256, 257, 364, 365
 routine coronary arteriography and revascularization in, 391-396
 "traditional" medical therapy for, 359-371
 treatment of, quality-of-life measurements in, 254, 255
 unusual causes of, case study of, 404, 405

Valsalva, sinus of. See *Sinus of Valsalva*.
 Valve(s), prosthetic, in the elderly, 153, 154
 Valve surgery, in the elderly, 224-227
 aortic, 225
 complications of, 226
 mitral, 224
 Valvular disease, in the elderly, 137-158. See also specific types, e.g., *Aortic valve disease, calcific*, *right-sided*, in the elderly, 152
 stress echocardiography in, 555-572
 Vascular catastrophe, mechanics of, 720
 Vasodilators, aortic function and, 732, 733
 Vein graft disease, degenerative, 411
 Ventricular arrhythmia(s), in the elderly, 189-195
 Vesalius, Andreas, 609
 Veterans Administration Non-Q Wave Infarction Strategies in Hospital trial, 379-381

Warfarin, 337, 338
 history of, 337, 338
 in prevention of unstable angina, 253
 mechanism of action of, 338
 Women, stress echocardiography in, 573-582

Xenografts, porcine, in aortic root replacement, 745

Yale Center for Thoracic Aortic Disease, 827, 828

